Information from the abstract
Importance Low-dose oral minoxidil (LDOM) is increasingly used off-label to treat pediatric hair disorders; however, standardized guidance for patient selection, dosing, safety, and monitoring in patients younger than 12 years is lacking. Objective To establish expert consensus recommendations for LDOM use in pediatric patients (age 10 pediatric patients treated with LDOM) and were invited to participate. Three iterative survey rounds were conducted using REDCap with multidisciplinary input. Consensus was defined as 70% or greater agreement on a 5-point Likert scale. Findings Of 51 experts, 50 from 9 countries completed rounds 1 and 2, and 49 (98.0% retention rate) completed round 3, reflecting broad international representation. Of 127 initial items considered, 84 achieved consensus. LDOM is supported for pediatric patients (aged ≥4 to
Why this record is monitored
This record has an Impact Signal of 80/100 based on recency, source, collaboration, and bibliographic signals. It prioritizes monitoring and is not a judgment of research quality.
Related topics: Hair Growth and Disorders · Facial Rejuvenation and Surgery Techniques · Skin and Cellular Biology Research
Thai researcher and institutional participation
Bruna Duque‐Estrada · Institute of Dermatology
Data limitations
This page is a bibliographic record based on abstract-level information, not a full analysis or quality assessment. Verify the DOI and original article before citation.